Recent Clinical Effect of Sarpogrelate Hydrochloride in Treatment of Chronic Lower Extremity Arteriosclerosis Obliterans_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

曾宏 , 孙晓磊 , 何虎强 , 刘勇

Corresponding author：

Keywords：

盐酸沙格雷酯; 慢性下肢动脉硬化闭塞症; 疗效

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　评价盐酸沙格雷酯治疗慢性下肢动脉闭塞症的有效性和安全性。
方法　对根据临床症状、下肢三维血管重建（CTA）或血管造影检查诊断为慢性下肢动脉硬化闭塞症的32例患者，采用盐酸沙格雷酯（100　mg/片）治疗，1片/次，3次/d，餐后口服，连续4周。用药24个月后观察患者临床症状的改善情况，分析盐酸沙格雷酯的治疗效果。
结果　用药24个月期间，失访3例，获访29例。综合疗效显效6例，良好15例，改善5例，无效3例，总有效率为89.7% （26/29）。治疗前后患者的凝血系统和临床生化各指标比较差异均无统计学意义（P＞0.05）。用药后3例（10.3%）患者出现轻度恶心和胃部不适，2例（6.9%）患者出现轻度皮疹，其余患者均无不良反应出现。安全性评价安全没问题24例，稍有问题5例。
结论　盐酸沙格雷酯可以改善慢性下肢动脉硬化闭塞症患者的临床症状。

Citation： 曾宏,孙晓磊,何虎强,刘勇. Recent Clinical Effect of Sarpogrelate Hydrochloride in Treatment of Chronic Lower Extremity Arteriosclerosis Obliterans. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(6): 661-663. doi: Copy

1.	Selvin E， Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States：results from the National Health and Nutrition Examination Survey， 1999-2000　[J]. Circulation， 2004， 110(6)：738-743.
2.	Guan H， Li YJ， Xu ZR， et al. Prevalence and risk factors of peripheral arterial disease in diabetic patients over 50 years old in China　[J]. Chin Med Sci J， 2007， 22(2)：83-88.
3.	Hoyer D， Clarke DE， Fozard JR， et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)　[J]. Pharmacol Rev， 1994， 46(2)：157-203.
4.	Nagatomo T， Rashid M， Abul Muntasir H， et al. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system[J]. Pharmacol Ther， 2004， 104(1)：59-81.
5.	Golino P， Piscione F， Willerson JT， et al. Divergent effects ofserotonin on coronary-artery dimensions and blood flow in patientswith coronary atherosclerosis and control patients　[J]. N Engl J Med， 1991， 324(10)：641-648.
6.	-hydroxytryptamine2C)：where structure meets function　[J]. Pharmacol Ther， 1998， 79(3)：231-257.
7.	Saxena PR， Villalón CM. Cardiovascular effects of serotonin agonists and antagonists　[J]. J Cardiovasc Pharmacol， 1990， 15 Suppl 7：S17-S34.
8.	Roth BL， Willins DL， Kristiansen K， et al. 5-hydroxytryptamine2-family receptors (5-hydroxytryptamine2A， 5-hydroxytryptamine2B，.
9.	王玉珍，李翔，许樟荣，等. 沙格雷酯与阿司匹林治疗糖尿病下肢血管病变的随机、对照临床研究　[J]. 中华内分泌代谢杂志， 2009， 25(6)：595-597.
10.	Hara H， Osakabe M， Kitajima A， et al. MCI-9042， a new antiplatelet agent is a selective S2-serotonergic receptor antagonist　[J]. Thromb Haemost， 1991， 65(4)：415-420.
11.	Nakamura K， Kariyazono H， Moriyama Y， et al. Effects of sarpogrelate hydrochloride on platelet aggregation， and its relation to the release of serotonin and P-selectin　[J]. Blood Coagul Fibrinolysis， 1999， 10(8)：513-519.
12.	Sharma SK， Zahradka P， Chapman D， et al. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate　[J]. J Pharmacol Exp Ther， 1999， 290(3)：1475-1481.
13.	Maruyama K， Kinami J， Sugita Y， et al. MCI-9042：high affinity for serotonergic receptors as assessed by radioligand binding assay　[J]. J Pharmacobiodyn， 1991， 14(4)：177-181.
14.	He M， Qin X， Cui Y， et al. Prevalence of unrecognized lower extremity peripheral arterial disease and the associated factors in Chinese hypertensive adults　[J]. Am J Cardiol， 2012， 110(11)：1692-1698.
15.	Ma H， Kandil A， Haqqani OP， et al. Endovascular treatment of stenoses in a pediatric patient with incomplete aortic duplication， mesenteric ischemia， and renovascular hypertension　[J]. J Vasc Surg， 2013， 57(1)：214-217.
16.	Cherviakov IuV， Staroverov IN， Nersesian EG， et al. Therapeuticangiogenesis in treatment of patients with chronic obliterating diseases of lower limb arteries　[J]. Angiol Sosud Khir， 2012， 18(3)：19-27.

1. Selvin E， Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States：results from the National Health and Nutrition Examination Survey， 1999-2000　[J]. Circulation， 2004， 110(6)：738-743.
2. Guan H， Li YJ， Xu ZR， et al. Prevalence and risk factors of peripheral arterial disease in diabetic patients over 50 years old in China　[J]. Chin Med Sci J， 2007， 22(2)：83-88.
3. Hoyer D， Clarke DE， Fozard JR， et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)　[J]. Pharmacol Rev， 1994， 46(2)：157-203.
4. Nagatomo T， Rashid M， Abul Muntasir H， et al. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system[J]. Pharmacol Ther， 2004， 104(1)：59-81.
5. Golino P， Piscione F， Willerson JT， et al. Divergent effects ofserotonin on coronary-artery dimensions and blood flow in patientswith coronary atherosclerosis and control patients　[J]. N Engl J Med， 1991， 324(10)：641-648.
6. -hydroxytryptamine2C)：where structure meets function　[J]. Pharmacol Ther， 1998， 79(3)：231-257.
7. Saxena PR， Villalón CM. Cardiovascular effects of serotonin agonists and antagonists　[J]. J Cardiovasc Pharmacol， 1990， 15 Suppl 7：S17-S34.
8. Roth BL， Willins DL， Kristiansen K， et al. 5-hydroxytryptamine2-family receptors (5-hydroxytryptamine2A， 5-hydroxytryptamine2B，.
9. 王玉珍，李翔，许樟荣，等. 沙格雷酯与阿司匹林治疗糖尿病下肢血管病变的随机、对照临床研究　[J]. 中华内分泌代谢杂志， 2009， 25(6)：595-597.
10. Hara H， Osakabe M， Kitajima A， et al. MCI-9042， a new antiplatelet agent is a selective S2-serotonergic receptor antagonist　[J]. Thromb Haemost， 1991， 65(4)：415-420.
11. Nakamura K， Kariyazono H， Moriyama Y， et al. Effects of sarpogrelate hydrochloride on platelet aggregation， and its relation to the release of serotonin and P-selectin　[J]. Blood Coagul Fibrinolysis， 1999， 10(8)：513-519.
12. Sharma SK， Zahradka P， Chapman D， et al. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate　[J]. J Pharmacol Exp Ther， 1999， 290(3)：1475-1481.
13. Maruyama K， Kinami J， Sugita Y， et al. MCI-9042：high affinity for serotonergic receptors as assessed by radioligand binding assay　[J]. J Pharmacobiodyn， 1991， 14(4)：177-181.
14. He M， Qin X， Cui Y， et al. Prevalence of unrecognized lower extremity peripheral arterial disease and the associated factors in Chinese hypertensive adults　[J]. Am J Cardiol， 2012， 110(11)：1692-1698.
15. Ma H， Kandil A， Haqqani OP， et al. Endovascular treatment of stenoses in a pediatric patient with incomplete aortic duplication， mesenteric ischemia， and renovascular hypertension　[J]. J Vasc Surg， 2013， 57(1)：214-217.
16. Cherviakov IuV， Staroverov IN， Nersesian EG， et al. Therapeuticangiogenesis in treatment of patients with chronic obliterating diseases of lower limb arteries　[J]. Angiol Sosud Khir， 2012， 18(3)：19-27.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Recent Clinical Effect of Sarpogrelate Hydrochloride in Treatment of Chronic Lower Extremity Arteriosclerosis Obliterans

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content